Quotes 5-day view Delayed Nasdaq
01/15/2021
01/19/2021
01/20/2021
01/21/2021
01/22/2021
Date
63.33(c)
67.07(c)
67.99(c)
66.98(c)
66.94(c)
Last
9 361 943
18 395 947
10 131 253
8 145 642
4 897 528
Volume
+1.49% +5.91% +1.37% -1.49% -0.06% Change
Sales 2020
24 303 M - -
Net income 2020
39,3 M - -
Net Debt 2020
24 871 M - -
P/E ratio 2020
1 175x
Yield 2020
4,04%
Sales 2021
24 407 M - -
Net income 2021
7 489 M - -
Net Debt 2021
20 836 M - -
P/E ratio 2021
10,9x
Yield 2021
4,20%
Capitalization
83 911 M 83 911 M -
EV / Sales 2020
4,48x
EV / Sales 2021
4,29x
Nbr of Employees
11 800
Free-Float
99,9%
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.5%): especially royalties and...
Notations Surperformance© of Gilead Sciences, Inc.
Trading Rating : Investor Rating :
All news about GILEAD SCIENCES, INC.
News in other languages on GILEAD SCIENCES, INC.
Analyst Recommendations on GILEAD SCIENCES, INC.
Gilead Sciences : raises 2020 profit forecast on remdesivir strength
Chart GILEAD SCIENCES, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends GILEAD SCIENCES, INC.
Short Term Mid-Term Long Term Trends Bullish Neutral Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
32
Average target price
72,64 $
Last Close Price
66,94 $
Spread / Highest target
49,4%
Spread / Average Target
8,52%
Spread / Lowest Target
-13,4%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
